ASCO Presentation: Abstract #3011 Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
Audio / Visual Presentation: Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
ASCO-SITC Clinical Immuno-Oncology Symposium SEMA4D-related Oral Presentation: CLASSICAL-Lung Combination Trial of Pepinemab with Avelumab
Detailed supporting data for ASCO Abstract #3011